Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Alpha Fetoprotein L1 Measurement

Known as: AFPL1, Alpha Fetoprotein L1 
The determination of the amount of alpha fetoprotein L1 present in a sample.
National Institutes of Health

Related topics

Related topics

3 relations
CDISC SDTM Laboratory Test Terminology by CodeCDISC SDTM Laboratory Test Terminology by NameClinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes
Despite the increased risks of cancers and cardiovascular related diseases, tobacco smoking continues to be prevalent in the… 
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2016
2016
Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)
Tobacco smoking is recognized as a global pandemic resulting in 6 million deaths per year. Despite a variety of anti-smoking… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
Nasal immunization of mice with AFCo1 or AFPL1 plus capsular polysaccharide Vi from Salmonella typhi induces cellular response and memory B and T cell responses.
The response to infection against Salmonella involves both B and T cell mediated immunity. An effective immunization can activate… 
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Review
2013
Review
2013
Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform
The development of effective vaccines against neglected diseases, especially those associated with poverty and social deprivation… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2010
Highly Cited
2010
Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice.
The purpose of this study was to investigate the potential of intranasal (IN) immunization with Neisseria meningitides B… 
2009
2009
Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
Most pathogens either invade the body or establish infection in mucosal tissues and represent an enormous challenge for vaccine… 
Review
2009
Review
2009
Adjuvant strategies required for targeting mucosal tissues.
In recent years, as a result of decreasing public confidence in vaccination programmes, focus has moved towards the development… 
2009
2009
Intranasal immunization with AFCo1 induce systemic, mucosal and memory immune response in neonatal mice
Neonates have a poorly developed immune system. Respiratory pathogens cause disease during early periods of live. Consequently… 
  • figure 1
  • figure 2
Highly Cited
2007
Highly Cited
2007
New Vaccines Require Potent Adjuvants like AFPL1 and AFCo1
Neisseria meningitidis B proteoliposome (AFPL1 when used as adjuvant) and its derivative‐Cochleate (AFCo1) contain… 
2006
2006
NATURAL Neissera DERIVE PROTEOLIPOSOME AND COCHLEATE AS POTENT VACCINE ADJUVANTS
Summary Proteoliposome (AFPL1) and its derivated - Cochleate (AFCo1) contain immunopotentiating and immunomodulatory properties… 
  • figure 2
  • figure 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE